A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

► A first-in-human study of a bivalent rLP2086 N. meningitidis serogroup B vaccine. ► Healthy adults received placebo or ascending dose levels of bivalent rLP2086. ► Bivalent rLP2086 induced robust serum bactericidal activity against 6 diverse MnB strains. ► Most recipients (75-100%) of 60 μg or 200 μg doses had seroprotective (≥1:4) hSBA titres. ► The vaccine was well tolerated; adverse events were rare and generally mild or moderate.